Opus Genetics (IRD) Q3 2024 earnings summary

Executive summary

• Completed the acquisition of Opus Genetics in October 2024, expanding the pipeline to include seven AAV-based gene therapy assets and Phentolamine Ophthalmic Solution 0.75% for inherited retinal diseases and other ophthalmologic disorders.

• Shifted strategic focus to gene therapy programs, with APX3330 development to be advanced via partnership.

• RYZUMVI (Phentolamine Ophthalmic Solution 0.75%) launched commercially in April 2024; ongoing Phase 3 trials for additional indications.

• Four clinical data readouts expected in 2025, including two Phase 3 studies for Phentolamine and two gene therapy trials.

• Combined company renamed Opus Genetics, trading under ticker IRD as of October 24, 2024.

Financial highlights

• License and collaborations revenue was $3.9M for Q3 2024, down from $11.9M in Q3 2023 due to a prior year $10M milestone payment.

• Net loss of $7.5M for Q3 2024, or $(0.29) per share, compared to net income of $5.6M in Q3 2023; net loss of $22.4M for the nine months ended September 30, 2024.

• Cash and cash equivalents totaled $36.6M as of September 30, 2024.

• R&D expenses increased to $9.0M in Q3 2024 from $3.5M in Q3 2023, driven by clinical and manufacturing costs.

• General and administrative expenses rose to $2.9M in Q3 2024 from $2.1M in Q3 2023, mainly due to personnel and legal costs.

Outlook and guidance

• Cash runway projected to extend into 2026, supporting ongoing and planned clinical trials.

• Enrollment of first pediatric patients in LCA5 Phase 1/2 trial expected in Q1 2025, with data in Q3 2025.

• Topline data from ongoing Phase 3 trials for Phentolamine expected in 2025.

• OPGx-BEST1 Phase 1/2 trial to begin in Germany in 2025.

• Anticipates increased R&D expenses as gene therapy programs advance; expects continued net losses until further product approvals or significant revenue generation.